Anagenics Ltd has released a press release.
Nature Paper MK in Melanoma
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Anagenics
- Cellmids FGF5 inhibitor clinical study published
- Cellmid to Refinance R&D Loan Facility
- Cellmid: Appendix 4D and Half Year Accounts
- Midkine alopecia patent european allowance
- Cellmids usa midkine patent for alopecia allowed
Later from Anagenics
- Cellmid secures premium US retail channel for evolis
- Cellmid completes US consumer study
- Cellmid receives $947K R&D tax credit
- Proposed consolidation of securities
- Cellmid opens first concept store in tokyo
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics